Market Overview

UPDATE: Morgan Stanley Initiates Coverage on Relypsa on Large Opportunity in K+ Control

Share:

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Relypsa (NASDAQ: RLYP) with an Overweight rating and $57.00 price target.

In the report, Morgan Stanley noted, “We are OW Relypsa as we believe patiromer has $850+mn revenue potential in hyperK+. Patiromer has shown solid data reducing serum K+ levels in hyperkalemic patients out to 52 weeks. Patiromer's safety profile is clean, with manageable mild-to-moderate GI tolerability and low levels of hypokalemia and hypomagnesemia, which have not led to clinically meaningful issues. We expect patiromer to be approved in the US following a 3Q14 NDA filing; the EU path forward is less clear to us. Many HF and CKD patients must reduce or discontinue RAASi therapy, drugs which have been shown to improve long-term outcomes, given high K+ levels. We see a compelling opportunity for patiromer as the drug reduces K+ levels and may allow HF and CKD patients to remain on their RAASi therapy. We expect that limited long-term data and tolerability issues will moderate the impact of competitors such as ZS-9 and kayexalate.”

Relypsa closed on Monday at $19.99.

Latest Ratings for RLYP

DateFirmActionFromTo
Sep 2016BTIG ResearchTerminatesNeutral
Aug 2016Stifel NicolausDowngradesBuyHold
Aug 2016OppenheimerTerminatesOutperform

View More Analyst Ratings for RLYP
View the Latest Analyst Ratings

 

Related Articles (RLYP)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com